Title: Is Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation?
Abstract: OBJECTIVE: The objective of this EBM review is to determine whether or not Apixaban is effective for the prevention of stroke in patients with non-valvular atrial fibrillation. STUDY DESIGN: Review of three English language primary studies published all published in 2011. DATA SOUCRES: Three double-blind randomized control trials found using the Cochrane Database and PubMed. OUTCOME(S) MEASURED: Outcomes measured were occurrence of stroke (TIA or CVA), systemic embolism, major bleeding or clinically relevant non-major bleeding, and incidence of death. RESULTS: Apixaban 2.5mg and 5mg were both superior to Warfarin in the prevention of stroke or systolic embolism and also decreased the rate of intracranial hemorrhage or other clinically relevant bleeding. Apixaban 5mg was also demonstrated superiority compared to aspirin 81-324mg in reduction of stroke, systemic embolism, and death rates. CONCLUSION: In patients with atrial fibrillation, apixaban was superior to both warfarin (adjusted to an INR 2.0-3.0) and aspirin (81-324mg) in the indication of prevention of stroke or systemic embolism.
Publication Year: 2014
Publication Date: 2014-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot